A tertiary care centre experience with Elranatamab: A report of three cases.

Autor:	Kakkar D; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India., Singh A; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India., Pillai RH; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India., Panda T; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India., Palatty RJ; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India., Halder R; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India., Agrawal N; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India., Bhurani D; Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India.
Jazyk:	angličtina
Zdroj:	Leukemia research reports [Leuk Res Rep] 2024 Jun 13; Vol. 21, pp. 100466. Date of Electronic Publication: 2024 Jun 13 (Print Publication: 2024).
DOI:	10.1016/j.lrr.2024.100466
Abstrakt:	Introduction: The introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the treatment paradigm of multiple myeloma. With the advent of these new therapeutic options, life expectancy has substantially increased for myeloma patients which has led to an increased number of patients with triple-class refractory disease. Thus, there remains an unmet need for effective novel therapies with good tolerability and safety profile. Elranatamab, is the most widely used bispecific antibody currently in the Indian setting. However, it has only been used on a clinical trial basis till now, and real-world data especially in the Indian setting is missing. Here, we present our experience with three cases of multi-line treated relapsed/refractory multiple myeloma on elranatamab monotherapy. Case Report: We here discuss three of our patients with triple class refractory multiple myeloma who recieved elranatamab monotherapy. While one of our patient had been switched to fortnightly treatment, two patients were still continuing weekly treatment. The common adverse effects observed were grade 1-2 cytokine release syndrome, cytopenias, CMV reactivation and hypo-gammaglobulinemia. While two of our patients are doing well, one patient had grade 3 neurological toxicity, likely drug related and succumbed. Discussion: B-cell maturation antigen is highly expressed on mature B cells and is critical for the survival and proliferation of plasma cells. It has emerged as a novel target for anti-myeloma therapies in the form of bispecific cell engager, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapies.The phase II MM3 trial showed a promising efficacy with an ORR of 61% with a CR rate of >35%. With a median follow-up of 14.7 months, the median PFS was not reached and the 15-month PFS rate was 50.9%. While it is too early to comment on long term survival with the monotherapy, we here discuss response of Indian patients in the real world setting. Conclusion: Elranatamab monotherapy could prove to be an efficacious option for the treatment of relapsed /refractory multiple myeloma patients with triple-class refractory disease, with limited therapeutic options. However, patients need to be screened for infectious complications with appropriate prophylaxis and immunoglobulin replacement, if required. Also, a high suspicion is required for the neurological complications of the drug and a longitudinal neuro-cognitive screening is required for the patients. Competing Interests: NilNil (© 2024 The Author(s). Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu